Theralase(R) Releases Q1 2026 Financial Statements

Theralase(R) Provides an Update on its Phase II Bladder Cancer Clinical Study Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's unaudited interim consolidated financial statements for the three-month period ended March 31st, 2026 ("Financial Statements"). Theralase® will be hosting a conference call on June 9 th at 11:00 am ET, which will include a presentation of the financial and operational results for the quarter ended March 31st, 2026.